Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis

Inclusion Criteria: Male or female >= 1 day old (newborn, infant, child, adult); written informed consent by patient or legally acceptable representative; purulent bacterial conjunctivitis (unilateral or bilateral) defined as bulbar conjunctival injection (mild, moderate, or severe) AND conjunctival purulent discharge (mild, moderate or severe). Exclusion Criteria: Bacterial conjunctivitis diagnosed >= 7 days ago; bacterial infection due to trauma or foreign body; dacryocystitis; corneal ulceration or keratitis; viral ocular infection; closed angle glaucoma; acute allergy conjunctivitis; clinically significant ocular abnormality; organic amblyopia, monophthalmia; corrected visual acuity below 20/100; contact lens wearer; newborn (i.e. 0-2 months old) not born at term (< 37 weeks of amenorrhea); ocular surgery, laser in situ keratomileusis (LASIK), laser epithelial keratomileusis (LASEK), or photo-refractive keratectomy (PRK) in last 12 months; ocular laser treatment in last 3 months; systemic macrolide antibiotics in last month; systemic steroids in last 2 weeks or during the study; topical ocular macrolide antibiotics and/or topical ocular steroids and/or non-steroidal anti-inflammatory drugs (NSAIDs) in last week; topical (ocular, nasal, bronchial etc.) treatments and/or systemic NSAIDs in last day; immunosuppressives and/or any systemic antibiotic on D0.